LTA and graft versus host disease: Chiang et al. described the use of a humanized anti-LTα monoclonal antibody (MLTA3698A) that specifically depleted activated LT-expressing human donor T and B cells, resulting in prolonged survival times in the hu-SCID mouse model of GVHD (25).